Introduction

Infectious diseases including HIV and viral hepatitis constitute major health issues, with particularly high prevalence among injecting drug users (IDUs). Viral hepatitis is a potential major health issue that can be caused by different etiologic agents. These types of infections are spread worldwide, although their prevalence varies in different regions. It is estimated that there are approximately 350 million carriers of hepatitis B virus (HBV) in the world, with one million deaths per year as a consequence of hepatitis B. Also, more than 150,000 people are infected with hepatitis C virus (HCV) each year in the US, and approximately 20 to 30% of these patients are at risk for developing cirrhosis. Blood-borne hepatitis can become a chronic infection at proportions which vary depending on the causative agent. Among adults with HBV infection, 5–10% can become chronic and a higher frequency (90%) is observed in HCV, a super infection. Liver cirrhosis and hepatocellular carcinoma are two of the major complications of viral hepatitis. HBV is associated with fulminate hepatitis in approximately 1–2% of acute cases, whereas HCV is rarely associated with this complication. Injecting drug users (IDUs) belong to a section of population, more frequently exposed to many viral infections,
including HBV, HCV, and HIV.[8] Furthermore, these subjects play a role as a reservoir and source of viral transmission in the intra- and extra-exposure categories. The prevalence of blood-borne hepatitis is usually higher among IDU than in other comparable non-IDU population strata.[9] Epidemiological data indicate that IDUs represent the largest risk group for HCV infection.[10] The aim of the present study was to assess the frequency of HBV, HCV, and HIV infections and their respective risk factors among IDUs from Kashan, a region of unknown endemicity for HBV infection.

MATERIALS AND METHODS

IDU population and testing

The subject for this research included 200 injecting drug users hospitalized between 2001 and 2006, at Shehid Beheshti Hospital, Kashan, a city 200 km south of Tehran, Iran. The patients voluntarily participated in the study. The injecting users were hospitalized at the infection ward of the hospital. According to ethical guidelines, formal consent was obtained from each individual, who was interviewed using a standardized questionnaire including questions regarding socio-demographic status. All subjects were tested for the presence of anti-HBc, HBsAg, anti-HCV, and anti-HIV infection by drawing 5 cc of their blood samples. Serological markers including HBsAg, anti-HCV antibodies, and HIV were assessed by ELISA method using Monobid kits made in the US. Demographic data was collected by using a researcher designed questionnaire.

Statistical analysis

Following the completion of data collection for all the participants, statistical analysis were performed using the SPSS:pc version 15.0. The results of analysis are presented in Table 1. Tests of association between gender and affliction to infectious diseases were also performed using chi-square and Fisher's exact test (Yates corrected) and t-test for means were employed. Results were regarded at the P value set to 0.05.

RESULTS

In this research, 200 IDUs were examined. The results of analysis indicated that 177 patients were males (88.5%) and 23 were females (11.5%). The mean age of the subjects was 36.5 ± 10.2 years. The results of test analysis performed in lab revealed that the frequency of positive infection among the male with regards to HBV, HCV, and HIV was 4% (8 cases), 10.5% (21 cases), and 1.5% (3 cases); and for female it was 0.5% (1 case), 1.5% (3 cases), and 0% (0 case), respectively. These results are presented in Table 1. The results of demographic data analysis showed that 73% (146) individuals had under diploma degree and 27% (54) patients had higher than high school diploma; and all the HIV patients had less than diploma education. Also, 1% (2) had HBV and HCV simultaneously; whereas, none of the patient suffered from HBV, HCV, and HIV at the same time.

In addition, Chi square test was used to examine the relationship between gender and addition. The results of analysis showed that there was no significant association between these factors (P > 0.05), nor there was any significant association between the marital status and IVD (P > 0.05).

DISCUSSION

The present study shows a high prevalence of blood-borne viral hepatitis among IDUs from Kashan, a region of unknown endemicity for HBV infection. The frequency of HBsAg found in this study (4.5%) for men was within the range of approximately 1.30−8.69% by other researchers.[10,11] But, this was relatively lower than those observed in areas of high endemicity, with more than 8% of HBsAg prevalence studies of IDUs in Santos, SP, Brazil,[12] and 6.5% in Kabul, Afghanistan.[13] The frequency of HCV infection for male patients in this study was 11.9%, whereas 1.3% for female subjects. However, no significant association was found between the gender and affliction to this infection. These results are similar to those reported in a study conducted in China.[14] As HBV and HCV have the same transmission routes, dual infection may occur. Patients coinfected with HBV and HCV may have more severe liver disease and high mortality rate (10%).[15,16]

As De Jarlais[17] pointed, IDUs constitute an important source of viral infections and therefore can play an important role in the transmission of viruses to the general population. Hence, a public health intervention with the implementation of comprehensive prevention programs including information, face-to-face education, empowerment.

| Gender marker | Male % (+/N) | Female % (+/N) |
|---------------|-------------|---------------|
| HBsAg         | 4.5 (8/177) | 0.04 (1/23)   |
| HCV           | 11.9 (21/177)| 1.3 (3/23)    |
| HIV           | 1.6 (3/177)  | 0 (0/23)      |
| Total         | 18 (32/177)  | 1.7 (4/23)    |
strategies, distribution or exchange of clean injecting equipment and distribution of condoms must be encouraged. These measures are especially relevant in developing countries such as Iran, Afghanistan, and Brazil; where Public Health programs are under budgeted and understaffed, and frequently lack expertise and political support for implementation.

REFERENCES

1. Purcell RH. The hepatitis viruses: an overview. In: Nishioka K, Suzuki H, Mishiro S and Oda T (Editors), Viral Hepatitis and Liver Disease. Springer Verlag: Tokyo, Japan; 1995.

2. Groscheide P and van Damme P. Prevention and control of hepatitis B in the community. In: Hallauer J, Kane M, McCoy E, Mellea A and Moure C (Editors), Communicable Diseases Series. 1. World Health Organization: Geneva; 1996.

3. Hadziyannis SJ. Hepatitis delta: an overview. In: Rizzetto M, Purcell RH, Gerin JL and Verme G (Editors), Viral Hepatitis and Liver Disease. Edizioni Minerva Medica: Rome, Italy; 1997. p. 283-9.

4. Gish RG, Lau JYN. Hepatitis C virus: eight years old. Viral Hepatitis Reviews 1997;1:17-37.

5. Moyer LA, Mast EE. Hepatitis B: Virology, epidemiology, disease and prevention and an overview of viral hepatitis. Am J Prev Med 1994;10:45-55.

6. Purcell RH, Gerin JL. Hepatitis delta virus. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B and Strauss SE (Editors), Fields Virology. Vol. 2. Lippincott-Raven Publishers: Philadelphia; 1996. p. 2819-29.

7. Colombo M. Hepatocellular carcinoma: An overview. In: Rizzetto M, Purcell RH, Gerin JL and Verme G (Editors), Viral Hepatitis and Liver Disease. Edizioni Minerva Medica: Rome, Italy; 1997. p. 479-83.

8. Telles PR, Bastos FI, Guydish J, Inciardi JA, Surratt HL, Pearl M, et al. Risk behavior and HIV seroprevalence among injecting drug users in Rio de Janeiro, Brazil. AIDS 1997;11:835-42.

9. Dan M, Rock M, Lilos P, Shany SB. Seroprevalence of hepatitis B and hepatitis D virus infection among intravenous drug addicts in Israel. Int J Epidemiol 1993;22:140-3.

10. Massarat S, Malekzadeh R, Rezvan H. Hepatitis B in Iran. Arch Iranian Med 2000;3:192-201.

11. Farhat A, Khademi G, Mazlouman SI. The prevalence of hepatitis B carrier state in Khorassan province of Iran. Saudi Med J 2003;24:549-51.

12. Carvalho HB, Mesquita E, Massad E, Bueno TC, Lopes GT, Ruiz MA and Burattini MN (1995). HIV and infections of similar transmission patterns in a drug injectors community of Santos, Brazil. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;12:84-92.

13. Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis 2007;13:1327-31.

14. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: Systematic review and meta-analysis. Public Health 2008;122:990-1003.

15. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: Clinical and histological study in Saudi patients. Hepatogastroenterology 1997;44:1404-6.

16. Perumalswami PV, Bini EJ. Epidemiology, natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Minerva Gastroenterol Dietol 2006;52:145-55.

17. De Jarlais DC, Stimson GV, Hagan H, Perlman D, Choopanya K, Bastos FI, Friedman SR. Emerging infectious diseases and the injection of illicit psychoactive drugs. Current Issues in Public Health 1996;2:130-7.

Source of Support: Nil, Conflict of Interest: None declared.

ERRATUM

Indian Journal of Sexually Transmitted Diseases and AIDS December 2008; Vol 29; Issue 2

Title: Leprosy presenting as immune reconstitution inflammatory syndrome

Page 96; Authors: Sujata Mehta, Bela Padhiar, Bela Shah

Should read as Sujata R. Mehta, Bela Padhiar, Umesh Karia, Bela J. Shah

The error is regretted - Editor, IJSTD